Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 1,786 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $18.74, for a total transaction of $33,469.64. Following the transaction, the chief executive officer owned 339,392 shares of the company’s stock, valued at $6,360,206.08. This represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.

Bicara Therapeutics Stock Performance

BCAX traded down $0.03 during midday trading on Friday, reaching $18.47. 471,766 shares of the company were exchanged, compared to its average volume of 493,829. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.25 and a beta of -0.78. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71. The company’s fifty day moving average price is $16.47 and its 200 day moving average price is $15.75.

Analyst Upgrades and Downgrades

BCAX has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Citigroup initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Finally, Wells Fargo & Company upped their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.33.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP lifted its stake in Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after purchasing an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $44,484,000. Vanguard Group Inc. increased its position in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares during the last quarter. Finally, State Street Corp raised its stake in Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.